Quinoxaline-Based Monoamine Oxidase Inhibitors: Design Strategies, Synthesis, Structure-Activity Relationships, and Therapeutic Potential in Neurological Disorders: A Review From 1996 to 2026.
Quinoxaline-Based Monoamine Oxidase Inhibitors: Design Strategies, Synthesis, Structure-Activity Relationships, and Therapeutic Potential in Neurological Disorders: A Review From 1996 to 2026.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Jammu, IN · Author affiliation
Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.Location evidence
Ghāziābād, IN · Author affiliation
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.Location evidence
Kochi, IN · Author affiliation
Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Monoamine oxidases (MAOs) are key enzymes involved in the metabolism of neurotransmitters and play a significant role in the pathophysiology of neurological disorders such as depression, Parkinson's disease, and Alzheimer's disease. Inhibition of MAOs, particularly MAO-A and MAO-B, has emerged as a promising therapeutic strategy. Quinoxaline is an emerging scaffold with promising biological activities against various molecular targets, owing to its rich repertoire of bioactive molecules. Due to their favorable pharmacological profiles and structural versatility, quinoxaline derivatives have gained considerable attention among the various scaffolds explored. This review highlights rational design strategies for developing quinoxaline-based MAO inhibitors, focusing on structure-activity relationships (SARs) that govern their potency and selectivity. Modifications at specific positions of the quinoxaline ring system and the nature of substituents have demonstrated significant impacts on MAO-A versus MAO-B selectivity, metabolic stability, and blood-brain barrier permeability. This review primarily focuses on elucidating recent advancements in quinoxaline scaffolds targeting MAO inhibitors, including structural developments, structural-activity relationships (SAR), and potential therapeutic applications in neurological disorders, to help researchers develop a new generation of MAO inhibitors.